Printer Friendly

Aprecia, Cycle Collaborate to Develop 3D-Printed Orphan Drugs.

M2 PHARMA-December 14, 2017-Aprecia, Cycle Collaborate to Develop 3D-Printed Orphan Drugs

(C)2017 M2 COMMUNICATIONS

- Cincinnati, Ohio-based drug delivery technology platform company Aprecia Pharmaceuticals, LLC and Cambridge, UK-based Cycle Pharmaceuticals, Ltd. have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (3DP) technology, the company said.

The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia's proprietary 3DP ZipDose Technology platform.

ZipDose is the only known three-dimensional printing technology used in a pharmaceutical drug product approved by the US Food and Drug Administration.

Antonio Benedetti, CEO of Cycle said: "Aprecia's ZipDose 3DP technology can formulate fast-melt pharmaceutical products, incorporating significantly higher amounts of active pharmaceutical ingredient than any other fast-melt technology on the market.

As such, this advanced technology can uniquely overcome both pill burden and dysphagia swallowing difficulties both of which are life-long, daily issues for so many rare disease patients."

Aprecia expects to use its ZipDose Technology to transform the way people take medicine. It can be combined with a wide variety of active pharmaceutical ingredients to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer.

Aprecia is committed to enhancing the patient experience through novel approaches to drug delivery that address unmet treatment needs to eliminate patient suffering and caregiver burden.

Cycle is a pharmaceutical company that optimises and increases access to existing pharmaceuticals.

The company focuses on iImproving orphan drugs, reinstating generic drug products that have been previously marketed, and working with academic and other partners to extend pharmaceuticals to new medical areas where there is clear unmet need.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 14, 2017
Words:283
Previous Article:Arrakis Therapeutics Licenses University of Pennsylvania for Access to RNA-targeted Small Molecule Technology.
Next Article:56% of US Consumers Don't Know Obamacare Open Enrollment Ends This Friday.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters